Role of the nuclear receptor Rev-erb-α in the function of the sarcoplasmic reticulum of skeletal muscle : physiological and pathological implications

Au sein du muscle squelettique, le réticulum sarcoplasmique occupe une place essentielle dans la régulation de l’homéostasie calcique et de la contraction musculaire. En particulier, le transporteur calcique SERCA, situé à la membrane du réticulum endoplasmique permet de reconstituer le contenu calcique réticulaire suite à une contraction musculaire. Dans le muscle squelettique, l’activité de SERCA est contrôlée par un peptide inhibiteur spécifique appelé la myoréguline. Nous nous intéressons au rôle du récepteur nucléaire Rev-erb-α, un répresseur de transcription connu pour favoriser la fonction musculaire et dont l’activité peut être modulée par des ligands pharmacologiques. Nos résultats montrent que Rev-erb-α réprime l’expression de la myoréguline en se fixant sur son promoteur, ce qui a pour conséquence l’augmentation de l’activité de SERCA et la hausse du contenu calcique réticulaire. Un traitement avec un agoniste de Rev-erb-α, le SR9009, améliore l’homéostasie calcique et la contractilité musculaire de souris mdx/utr+/-, un modèle de la myopathie de Duchenne. Par ailleurs, le réticulum endoplasmique est le siège de la conformation des protéines de la voie sécrétoire. Des altérations de la conformation protéique provoquent un stress réticulaire et le déclenchement de la réponse aux protéines mal-conformées qui peut conduire jusqu’à l’apoptose. Il est décrit que le stress réticulaire est un phénomène impliqué dans l’activation de la cellule satellite musculaire suite à une blessure. Nous avons établi que Rev-erb-α, en augmentant l’interaction entre le réticulum endoplasmique et la mitochondrie accroit l’activation de la réponse aux protéines mal-conformées et l’apoptose de cellules satellites activées, ce qui pourrait impacter le potentiel de régénération musculaire. En conclusion, nous avons identifié Rev-erb-α comme un modulateur de la fonction du réticulum endoplasmique dans le muscle squelettique. Dans le futur, des thérapies ciblant spécifiquement Rev-erb-α pourraient être développées dans le cadre de pathologies musculaires chez l’Homme.Within skeletal muscle, the sarcoplasmic reticulum plays an essential role in the regulation of calcium homeostasis and muscle contraction. In particular, the SERCA transporter, located at the membrane of the endoplasmic reticulum, by pumping calcium from cytosol from reticular lumen, allows the reticular calcium content to be reconstituted following muscle contraction. In skeletal muscle, SERCA activity is controlled by a specific inhibitory peptide called myoregulin. We are interested in the role of the nuclear receptor Rev-erb-α, a transcription repressor known to promote muscle function and whose activity can be modulated by pharmacological ligands. Our results show that Rev-erb-α represses the expression of myoregulin by binding to its promoter, which results in an increase in SERCA activity and an increase in reticular calcium content. Treatment with a Rev-erb-α agonist, SR9009, improves calcium homeostasis and muscle contractility in mdx/utr+/- mice, a model of Duchenne myopathy. In addition, the endoplasmic reticulum is the site of protein conformation of the secretory pathway. Alteration in protein conformation causes reticular stress and triggers the unfolded protein response that can lead to apoptosis. It is described that reticular stress is a phenomenon involved in the activation of skeletal muscle satellite cell following an injury. We have established that Rev-erb-α, by increasing the interaction between endoplasmic reticulum and mitochondria enhances the activation of unfolded protein response and apoptosis of activated satellite cells, which could impact the muscle regeneration capacity. In conclusion, we have identified Rev-erb-α as a modulator of endoplasmic reticulum function in skeletal muscle. In the future, specific Rev-erb-α targeting therapies may be developed for human muscle diseases

Mitochondria and endoplasmic reticulum: Targets for a better insulin sensitivity in skeletal muscle?

International audienceObesity and its associated metabolic disorders represent a major health burden, with economic and social consequences. Although adapted lifestyle and bariatric surgery are effective in reducing body weight, obesity prevalence is still rising. Obese individuals often become insulin-resistant. Obesity impacts on insulin responsive organs, such as the liver, adipose tissue and skeletal muscle, and increases the risk of cardiovascular diseases, type 2 diabetes and cancer. In this review, we discuss the effects of obesity and insulin resistance on skeletal muscle, an important organ for the control of postprandial glucose. The roles of mitochondria and the endoplasmic reticulum in insulin signaling are highlighted and potential innovative research and treatment perspectives are proposed

Rev-erb-α : une cible thérapeutique contre la perte de masse musculaire ?

International audienc

Expression of the Pro-Fibrotic Marker Periostin in a Mouse Model of Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is characterised by fibrotic tissue deposition in skeletal muscle. We assessed the role of periostin in fibrosis using mdx mice, an established DMD murine model, for which we conducted a thorough examination of periostin expression over a year. RNA and protein levels in diaphragm (DIA) muscles were assessed and complemented by a detailed histological analysis at 5 months of age. In dystrophic DIAs, periostin (Postn) mRNA expression significantly exceeded that seen in wildtype controls at all timepoints analysed, with the highest expression at 5 months of age (p &lt; 0.05). We found Postn to be more consistently highly expressed at the earlier timepoints compared to established markers of fibrosis like transforming growth factor-beta 1 (Tgf-β1) and connective tissue growth factor (Ctgf). Immunohistochemistry confirmed a significantly higher periostin protein expression in 5-month-old mdx mice compared to age-matched healthy controls (p &lt; 0.01), coinciding with a significant fibrotic area percentage (p &lt; 0.0001). RT-qPCR also indicated an elevated expression of Tgf-β1, Col1α1 (collagen type 1 alpha 1) and Ctgf in mdx DIAs compared to wild type controls (p &lt; 0.05) at 8- and 12-month timepoints. Accordingly, immunoblot quantification demonstrated elevated periostin (3, 5 and 8 months, p &lt; 0.01) and Tgf-β1 (8 and 12 months, p &lt; 0.001) proteins in the mdx muscle. These findings collectively suggest that periostin expression is a valuable marker of fibrosis in this relevant model of DMD. They also suggest periostin as a potential contributor to fibrosis development, with an early onset of expression, thereby offering the potential for timely therapeutic intervention and its use as a biomarker in muscular dystrophies.</p

Expression of the Pro-Fibrotic Marker Periostin in a Mouse Model of Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is characterised by fibrotic tissue deposition in skeletal muscle. We assessed the role of periostin in fibrosis using mdx mice, an established DMD murine model, for which we conducted a thorough examination of periostin expression over a year. RNA and protein levels in diaphragm (DIA) muscles were assessed and complemented by a detailed histological analysis at 5 months of age. In dystrophic DIAs, periostin (Postn) mRNA expression significantly exceeded that seen in wildtype controls at all timepoints analysed, with the highest expression at 5 months of age (p &lt; 0.05). We found Postn to be more consistently highly expressed at the earlier timepoints compared to established markers of fibrosis like transforming growth factor-beta 1 (Tgf-β1) and connective tissue growth factor (Ctgf). Immunohistochemistry confirmed a significantly higher periostin protein expression in 5-month-old mdx mice compared to age-matched healthy controls (p &lt; 0.01), coinciding with a significant fibrotic area percentage (p &lt; 0.0001). RT-qPCR also indicated an elevated expression of Tgf-β1, Col1α1 (collagen type 1 alpha 1) and Ctgf in mdx DIAs compared to wild type controls (p &lt; 0.05) at 8- and 12-month timepoints. Accordingly, immunoblot quantification demonstrated elevated periostin (3, 5 and 8 months, p &lt; 0.01) and Tgf-β1 (8 and 12 months, p &lt; 0.001) proteins in the mdx muscle. These findings collectively suggest that periostin expression is a valuable marker of fibrosis in this relevant model of DMD. They also suggest periostin as a potential contributor to fibrosis development, with an early onset of expression, thereby offering the potential for timely therapeutic intervention and its use as a biomarker in muscular dystrophies.</p

Les agrégats nucléaires dans la dystrophie musculaire oculopharyngée

La dystrophie musculaire oculopharyngée est une des maladies en rapport avec des expansions pathologiques de triplets nucléotidiques. Sa physiopathologie est encore imparfaitement connue même si la présence d'agrégats au niveau des noyaux de la fibre musculaire semble jouer un rôle déterminant. Les travaux fondamentaux présentés ici permettent de mieux comprendre leur composition et leur rôle délétère. Autant d'éléments qui pourraient déboucher sur des voies thérapeutiques nouvelles

Beneficial effects of resistance training on both mild and severe mouse dystrophic muscle function as a preclinical option for Duchenne muscular dystrophy

International audienc

Effect of CsA on OVL plantaris muscle in Mdx mice.

(A) Force drop following lengthening contractions (Fragility). n = 8–12 per group. (B) Absolute maximal force (P0). n = 9–12 per group. (C) Muscle weight. n = 6–8 per group n = 11–12 per group. (D) Rate of force development. n = 9–12 per group. CsA: cyclosporin A. Mdx+OVL: mechanically overloaded Mdx mice. Mdx+OVL+CsA: mechanically overloaded Mdx mice that received CsA. Mdx: non-overloaded Mdx muscle. o1, o3, and o4: significant different from Mdx (p < 0.05), (p < 0.001) and (p < 0.0001) respectively. c1: significant different from Mdx+OVL (p < 0.05).</p

Oculopharyngeal Muscular Dystrophy

International audienc